A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Crenezumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 24 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2017 Trial design presented at the Alzheimer's Association International Conference 2017
    • 05 Jul 2017 Planned End Date changed from 31 May 2017 to 28 Jun 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top